aspirin + atorvastatin + ramipril

This is a **fixed-dose combination** drug containing **aspirin (acetylsalicylic acid)**, **atorvastatin**, and **ramipril**, most commonly indicated for the **prevention of major cardiovascular events** in adults at high risk or with established cardiovascular disease. - **Aspirin** is an antiplatelet agent, inhibiting platelet aggregation via cyclooxygenase-1 (COX-1) blockade, reducing thrombus formation. - **Atorvastatin** is a statin, inhibiting HMG-CoA reductase to lower cholesterol synthesis, especially LDL cholesterol. - **Ramipril** is an angiotensin-converting enzyme (ACE) inhibitor, lowering blood pressure by blocking the conversion of angiotensin I to angiotensin II and providing vascular protection. Studies and clinical guidelines consistently show this combination reduces the risk of recurrent major adverse cardiovascular events, improves lipid and blood pressure control, and increases therapy adherence in patients with prior myocardial infarction or established atherosclerotic cardiovascular disease. Commercial formulations such as Trinomia and the CNIC-Polypill exist in various fixed doses. This polypill is included on the World Health Organization's list of essential medicines for secondary prevention of atherosclerotic cardiovascular disease[2][3][5][6].

Brand names

TrinomiaCNIC-polypill

Other names

acetylsalicylic acid + atorvastatin + ramiprilpolypill (acetylsalicylic acid + atorvastatin + ramipril)